BioHarvest Sciences (BHST) Competitors

$3.86 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.87 +0.01 (+0.26%)

As of 05/22/2026 07:37 PM Eastern

BHST vs. RZLT, ELYM, FBRX, PALI, and SOPH

Should you buy BioHarvest Sciences stock or one of its competitors? MarketBeat compares BioHarvest Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioHarvest Sciences include Rezolute (RZLT), Eliem Therapeutics (ELYM), Forte Biosciences (FBRX), Palisade Bio (PALI), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry.

How does BioHarvest Sciences compare to Rezolute?

BioHarvest Sciences (NASDAQ:BHST) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, BioHarvest Sciences had 7 more articles in the media than Rezolute. MarketBeat recorded 7 mentions for BioHarvest Sciences and 0 mentions for Rezolute. Rezolute's average media sentiment score of 0.00 beat BioHarvest Sciences' score of -0.30 indicating that Rezolute is being referred to more favorably in the news media.

Company	Overall Sentiment
BioHarvest Sciences	Neutral
Rezolute	Neutral

BioHarvest Sciences has higher revenue and earnings than Rezolute. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51M	2.19	-$11.14M	-$0.59	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

BioHarvest Sciences has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Rezolute has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Rezolute's return on equity of -58.82% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Rezolute	N/A	-58.82%	-54.48%

BioHarvest Sciences currently has a consensus target price of $10.00, indicating a potential upside of 159.07%. Rezolute has a consensus target price of $8.75, indicating a potential upside of 169.23%. Given Rezolute's stronger consensus rating and higher probable upside, analysts plainly believe Rezolute is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rezolute	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Rezolute beats BioHarvest Sciences on 9 of the 15 factors compared between the two stocks.

How does BioHarvest Sciences compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioHarvest Sciences has a consensus target price of $10.00, suggesting a potential upside of 159.07%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts clearly believe BioHarvest Sciences is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Eliem Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Eliem Therapeutics' return on equity of -47.03% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

BioHarvest Sciences has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
BioHarvest Sciences	$34.51M	2.19	-$11.14M	-$0.59	N/A

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

In the previous week, BioHarvest Sciences had 6 more articles in the media than Eliem Therapeutics. MarketBeat recorded 7 mentions for BioHarvest Sciences and 1 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.88 beat BioHarvest Sciences' score of -0.30 indicating that Eliem Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eliem Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioHarvest Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioHarvest Sciences beats Eliem Therapeutics on 9 of the 15 factors compared between the two stocks.

How does BioHarvest Sciences compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Forte Biosciences has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

In the previous week, BioHarvest Sciences had 7 more articles in the media than Forte Biosciences. MarketBeat recorded 7 mentions for BioHarvest Sciences and 0 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.00 beat BioHarvest Sciences' score of -0.30 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Neutral
BioHarvest Sciences	Neutral

Forte Biosciences currently has a consensus price target of $67.00, indicating a potential upside of 210.33%. BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 159.07%. Given Forte Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Forte Biosciences is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Forte Biosciences has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

BioHarvest Sciences has higher revenue and earnings than Forte Biosciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
BioHarvest Sciences	$34.51M	2.19	-$11.14M	-$0.59	N/A

Summary

Forte Biosciences beats BioHarvest Sciences on 9 of the 15 factors compared between the two stocks.

How does BioHarvest Sciences compare to Palisade Bio?

BioHarvest Sciences (NASDAQ:BHST) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Palisade Bio has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Palisade Bio's return on equity of -36.79% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Palisade Bio	N/A	-36.79%	-34.34%

11.8% of Palisade Bio shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioHarvest Sciences has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, Palisade Bio had 1 more articles in the media than BioHarvest Sciences. MarketBeat recorded 8 mentions for Palisade Bio and 7 mentions for BioHarvest Sciences. Palisade Bio's average media sentiment score of 0.67 beat BioHarvest Sciences' score of -0.30 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
BioHarvest Sciences	Neutral
Palisade Bio	Positive

BioHarvest Sciences has higher revenue and earnings than Palisade Bio. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51M	2.19	-$11.14M	-$0.59	N/A
Palisade Bio	$250K	1,353.92	-$16.78M	-$1.01	N/A

BioHarvest Sciences currently has a consensus target price of $10.00, suggesting a potential upside of 159.07%. Palisade Bio has a consensus target price of $10.20, suggesting a potential upside of 423.08%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Palisade Bio beats BioHarvest Sciences on 13 of the 17 factors compared between the two stocks.

How does BioHarvest Sciences compare to SOPHiA GENETICS?

SOPHiA GENETICS (NASDAQ:SOPH) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

SOPHiA GENETICS currently has a consensus price target of $7.50, indicating a potential upside of 53.69%. BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 159.07%. Given BioHarvest Sciences' higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

31.6% of SOPHiA GENETICS shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioHarvest Sciences has a net margin of -32.54% compared to SOPHiA GENETICS's net margin of -44.48%. SOPHiA GENETICS's return on equity of -62.74% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

In the previous week, BioHarvest Sciences had 6 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 7 mentions for BioHarvest Sciences and 1 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.00 beat BioHarvest Sciences' score of -0.30 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioHarvest Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioHarvest Sciences has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	4.33	-$79M	-$0.52	N/A
BioHarvest Sciences	$34.51M	2.19	-$11.14M	-$0.59	N/A

SOPHiA GENETICS has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Summary

SOPHiA GENETICS beats BioHarvest Sciences on 11 of the 16 factors compared between the two stocks.

Get BioHarvest Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHST vs. The Competition

Export

Metric	BioHarvest Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$75.72M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-6.54	18.74	21.22	25.65
Price / Sales	2.19	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	3.30	7.09	10.37	7.14
Net Income	-$11.14M	$24.45M	$3.57B	$335.98M
7 Day Performance	-1.53%	6.38%	6.40%	4.15%
1 Month Performance	-11.87%	2.43%	3.52%	2.54%
1 Year Performance	-38.63%	62.98%	34.02%	35.05%

BioHarvest Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHST BioHarvest Sciences	2.4399 of 5 stars	$3.86 flat	$10.00 +159.1%	-38.6%	$75.72M	$34.51M	N/A	N/A
RZLT Rezolute	2.1402 of 5 stars	$3.34 -1.8%	$8.75 +162.0%	-16.5%	$321.62M	N/A	N/A	40
ELYM Eliem Therapeutics	N/A	$10.80 -4.7%	N/A	+832.2%	$321.32M	N/A	N/A	9
FBRX Forte Biosciences	1.6425 of 5 stars	$23.11 -3.5%	$67.00 +189.9%	+154.3%	$320.91M	N/A	N/A	5
PALI Palisade Bio	2.299 of 5 stars	$1.83 +1.1%	$10.20 +457.4%	+141.6%	$317.65M	$250K	N/A	10	Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BHST) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioHarvest Sciences (BHST) Competitors

BHST vs. RZLT, ELYM, FBRX, PALI, and SOPH

How does BioHarvest Sciences compare to Rezolute?

Summary

How does BioHarvest Sciences compare to Eliem Therapeutics?

Summary

How does BioHarvest Sciences compare to Forte Biosciences?

Summary

How does BioHarvest Sciences compare to Palisade Bio?

Summary

How does BioHarvest Sciences compare to SOPHiA GENETICS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioHarvest Sciences (BHST) Competitors

BHST vs. RZLT, ELYM, FBRX, PALI, and SOPH

How does BioHarvest Sciences compare to Rezolute?

Does the media prefer BHST or RZLT?

Which has higher valuation and earnings, BHST or RZLT?

Which has more volatility and risk, BHST or RZLT?

Do insiders and institutionals hold more shares of BHST or RZLT?

Is BHST or RZLT more profitable?

Do analysts recommend BHST or RZLT?

Summary

How does BioHarvest Sciences compare to Eliem Therapeutics?

Do insiders & institutionals hold more shares of ELYM or BHST?

Do analysts recommend ELYM or BHST?

Is ELYM or BHST more profitable?

Which has better valuation and earnings, ELYM or BHST?

Which has more risk & volatility, ELYM or BHST?

Does the media refer more to ELYM or BHST?

Summary

How does BioHarvest Sciences compare to Forte Biosciences?

Which has more volatility & risk, FBRX or BHST?

Does the media prefer FBRX or BHST?

Do analysts recommend FBRX or BHST?

Do institutionals and insiders believe in FBRX or BHST?

Is FBRX or BHST more profitable?

Which has stronger valuation & earnings, FBRX or BHST?

Summary

How does BioHarvest Sciences compare to Palisade Bio?

Is BHST or PALI more profitable?

Do institutionals & insiders hold more shares of BHST or PALI?

Which has more volatility and risk, BHST or PALI?

Does the media refer more to BHST or PALI?

Which has preferable valuation & earnings, BHST or PALI?

Do analysts recommend BHST or PALI?

Summary

How does BioHarvest Sciences compare to SOPHiA GENETICS?

Do analysts rate SOPH or BHST?

Do institutionals and insiders hold more shares of SOPH or BHST?

Is SOPH or BHST more profitable?

Does the media prefer SOPH or BHST?

Which has better valuation & earnings, SOPH or BHST?

Which has more risk and volatility, SOPH or BHST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools